Dr. Reddy's Laboratories Ltd.

337 articles with Dr. Reddy's Laboratories Ltd.

• Dr. Reddy's to release Q1 FY 20 results on July 29, 2019

  7/10/2019

  Dr. Reddy's Laboratories Ltd. will announce results for the first quarter ended June 30, 2019 on Monday, July 29, 2019 after the Board Meeting.

• Dr. Reddy’s Announces the Launch of the Over-the-counter Store Brand Equivalent of Mucinex® D Extended Release Tablets in Two Strengths in the U.S. Market

  7/9/2019

  Dr. Reddy’s Laboratories Ltd. announced the launch of an over-the-counter (OTC) store-brand equivalent of Mucinex® D Extended Release Tablets in two strengths—Guaifenesin 600 mg and Pseudoephedrine HCl 60 mg, and Guaifenesin 1200 mg and Pseudoephedrine HCl 120 mg—in the United States market, as approved by the U.S. Food and Drug Administration.

• Dr. Reddy's Laboratories Announces First-to-market Launch of Carboprost Tromethamine Injection USP, 250 mcg/mL (1mL) Single-dose Vial in the U.S. Market

  7/3/2019

  Dr. Reddy’s Laboratories Ltd. announced the launch of Carboprost Tromethamine Injection USP, 250 mcg/mL (1mL) Single-dose Vial, a therapeutic equivalent generic version of Hemabate® injection, 250 mcg/mL, approved by the U.S. Food and Drug Administration.

• Dr. Reddy's Laboratories Announces the Launch of Tobramycin Inhalation Solution, USP in the U.S. Market

  6/25/2019

  Dr. Reddy’s Laboratories Ltd. announced the launch of Tobramycin Inhalation Solution, USP a therapeutic equivalent generic version of TOBI® (tobramycin) Inhalation Solution, approved by the U.S. Food and Drug Administration (USFDA).

• Dr. Reddy's Laboratories Announces the Launch of Phytonadione Injectable Emulsion USP, 10 mg/ml Single-Dose Ampules in the U.S. Market

  6/22/2019

  Dr. Reddy’s Laboratories Ltd. announced the launch of Phytonadione Injectable Emulsion USP, 10 mg/ml Single-Dose Ampules, a therapeutic equivalent generic version of Vitamin K1 (Phytonadione) Injectable Emulsion USP, 10 mg/ml, approved by the U.S. Food and Drug Administration.

• Dr. Reddy’s Laboratories Announces Entering into a Definitive Agreement to Sell Its Neurology Branded Products to Upsher-Smith Laboratories, LLC

  6/14/2019

  Dr. Reddy’s Laboratories Ltd. announces that it has entered into a definitive asset purchase agreement with Upsher-Smith Laboratories, LLC, pursuant to which Dr. Reddy’s would sell its US and select territory rights for ZEMBRACE® SYMTOUCH® 3 mg and TOSYMRA™ 10 mg, which are commercialized through its wholly owned subsidiary, Promius Pharma, LLC.

• Upsher-Smith Laboratories Enters Into Agreement To Acquire Tosymra™ (sumatriptan nasal spray) And Zembrace® SymTouch® (sumatriptan injection)

  6/13/2019

  Strategic Acquisition Diversifies Company's Portfolio and Provides New Options for Migraine Patients

• Dr. Reddy's Laboratories Limited Through Its Wholly Owned Subsidiary, Dr. Reddy’s Laboratories SA, Announces Positive Topline Results from Phase 2b Study of PPC-06 in Patients with Moderate to Severe Plaque Psoriasis

  6/10/2019

  Dr. Reddy’s Laboratories Ltd. announced positive topline results from its Phase 2b study of PPC-06 (formerly referred to as XP23829) in patients with moderate to severe plaque psoriasis.

• Dr. Reddy’s Laboratories Limited Announces Filing of Annual Report on Form 20-F - June 4, 2019

  6/4/2019

  Dr. Reddy’s Laboratories Limited announced that its Annual Report on Form 20-F, containing its annual consolidated financial statements for the fiscal year ended March 31, 2019 was filed with the United States Securities and Exchange Commission on June 3, 2019.

• Dr. Reddy’s Q4 & FY19 Financial Results

  5/17/2019

  Dr. Reddy’s Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY) today announced its consolidated financial results for the fourth quarter and full year ended March 31, 2019 under International Financial Reporting Standards (IFRS)

• Dr. Reddy's Laboratories Announces the Launch of Testosterone Gel, 1.62% (20.25 mg/1.25 g Pump Actuation) in the U.S. Market

  5/6/2019

  Dr. Reddy’s Laboratories Ltd. announced the launch of Testosterone Gel 1.62%, a therapeutic equivalent generic version of AndroGel® (testosterone gel) 1.62%, approved by the U.S. Food and Drug Administration

• Dr. Reddy's to Release Q4 and Full Year FY 19 Results on May 17, 2019

  4/17/2019

  Dr. Reddy's Laboratories Ltd. (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) will announce results for the fourth quarter and full year ended March 31, 2019 on Friday, May 17, 2019 after the Board Meeting.

• Dr. Reddy's Laboratories Announces Acquisition of ANDA Portfolio

  4/13/2019

  Dr. Reddy’s Laboratories Ltd. announced that it has entered into a definitive agreement to acquire a portfolio of 42 approved, non-marketed Abbreviated New Drug Applications in the U.S.

• Promius Pharma, LLC. (a Wholly Owned Subsidiary of Dr. Reddy’s Laboratories Ltd.) Announces the Sale and Assignment of the US Rights for Its Marketed Dermatology Brands to Encore Dermatology

  4/2/2019

  Dr. Reddy’s Laboratories Limited, through its wholly owned subsidiary Promius Pharma, LLC, announces the sale of its rights for SERNIVO® (betamethasone dipropionate) Spray, 0.05% and assignment of its rights to market and distribute, PROMISEB® Topical Cream and TRIANEX® 0.05% (Triamcinolone Acetonide Ointment, USP) in the United States, to Encore Dermatology.

• Dr. Reddy's Laboratories launches Tadalafil Tablets USP in the U.S. Market - March 27, 2019

  3/27/2019

  Dr. Reddy’s Laboratories Ltd. announced the launch of Tadalafil Tablets USP, a therapeutic equivalent generic version of Cialis (tadalafil) Tablets in the United States market, approved by the U.S. Food and Drug Administration (USFDA).

• Dr. Reddy's Laboratories Announces the Re-Launch of Its Buprenorphine and Naloxone Sublingual Film after Favorable Ruling in Patent Litigation

  2/20/2019

  The re-launch comes on the heels of a favorable decision issued by the United States Court of Appeals for the Federal Circuit concluding that Indivior had not shown that it is likely to succeed on its claim that Dr. Reddy’s product infringes U.S. Patent No. 9,931,305.

• Dr. Reddy's Laboratories launches Tadalafil Tablets USP in the U.S. Market

  2/12/2019

  Dr. Reddy’s Laboratories Ltd. announced the launch of Tadalafil Tablets USP, a therapeutic equivalent generic version of Adcirca Tablets in the United States market, approved by the U.S. Food and Drug Administration.

• 

  BioSpace Movers and Shakers: Feb. 8

  2/8/2019

  In this week's edition of Movers and Shakers, biopharma companies tap executives to serve in various leadership roles.

• Dr. Reddy's Laboratories Continues its Voluntary Nationwide Recall of Levetiracetam in 0.54% Sodium Chloride Injection 1500mg/100mL Due to Mislabeling

  2/4/2019

  Dr. Reddy’s Laboratories Ltd. announced that its wholly owned subsidiary, Dr Reddy’s Laboratories, Inc, is continuing its voluntary nationwide recall of lot ABD807 of Levetiracetam in 0.54% Sodium Chloride Injection, 1,500 mg/100 mL single-dose infusion bags to the hospital level in U.S.A.

• Dr. Reddy’s Q3 FY19 Financial Results

  2/1/2019

  Dr. Reddy’s Laboratories Ltd. announced its consolidated financial results for the quarter ended December 31, 2018 under International Financial Reporting Standards.